Partnership with Syrma Johari Medtech, a globally recognized medical device engineering and manufacturing organization, expands INBS’ global manufacturing capacity, strengthens
Companies to leverage and collaborate on research and development, distribution, and regulatory expertise to accelerate global adoption of intelligent testing technologies Alliance positions INBS to
NEW YORK, December 12, 2025 — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“Intelligent Bio Solutions” or the “Company”), a medical technology company delivering
NEW YORK, November 20, 2025 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company
Record quarterly revenue of $1.11 million, an increase of 32% sequentially and 28% year-over-year, driven by consumable cartridge sales and
Company Achieves Third Consecutive Quarter of Revenue Growth Revenue Increase of Approximately 32% Sequentially and 28% Year-Over-Year Driven by New
NEW YORK, October 30, 2025 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company
Multinational company employs approximately 3,000 staff within the UK and Ireland and more than 30,000 staff worldwide Large new customer
The Workplace Health & Safety Show (WHS Show) returns to Sydney this October as the flagship event in Australia’s leading series dedicated
Webinar: Thursday November 20th Time: 4PM AEDT | 9AM GST | 2PM JST | 10:30AM IST Discover a faster, non-invasive,
The Company is initiating clinical studies to further validate Intelligent Fingerprinting Drug Screening System INBS anticipates FDA 510(k) clearance in
In December 2024, INBS submitted its 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for review and
Company advanced efforts to secure U.S. FDA 510(k) clearance to advance on path towards planned U.S. market expansion beyond Forensic
Company anticipates fiscal fourth quarter sequential and year-on-year revenue growth of approximately 16% Company advanced efforts to secure U.S. FDA
FDA response expected within six weeks; Company remains focused on 2025 U.S. expansion NEW YORK, August 06, 2025 – Intelligent Bio Solutions
